Active

CASSIFARMA

Switched

BE0727381719

Rechtspersoon Private limited company 1 establishment

Familie de Bayostraat 55, 3000 Leuven Detailhandel in farmaceutische producten

Active for

7 year, 3 months

Financials

Financial year 2025

Worth noting

  • Little cash and receivables against the short-term debts.

Gross margin

€ 114,699

▲ 12% vs 2024

Profit

Growing

€ 66,323

▲ 14% vs 2024

Debts

Low

€ 544,031

▼ 11% vs 2024

CASSIFARMA from Leuven, company number BE0727381719, closed financial year 2025 with a result of € 66,323 after tax. For that financial year CASSIFARMA recorded a gross margin of € 114,699 and equity of € 398,795. Compared with financial year 2024, the result moved from € 58,284 to € 66,323. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 28, 2026.

What happened at CASSIFARMA?

What happened at CASSIFARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

  • New annual accounts for financial year 2025: profit of € 66,323 (▲ 14% vs 2024). Source: NBB ↗
  • New establishment in Leuven. KBO
  • Start of the company according to the CBE. KBO

In short

From € 50,173 profit in 2021 to € 66,323 profit in 2025.

Paid € 145,559 in corporate taxes since 2021.

Best year ever: 2023, with € 66,622 profit.

Paid out € 4,125 in dividends to the owners in total.

A new publication or filing at CASSIFARMA? We notify you, reason included.

Follow CASSIFARMA

Need more data?

History

Every financial year, as far back as the National Bank goes.

Buffer

How long does the company survive without income?

Credit limit

Indicative credit limit, computed from the real figures.

Alerts

New annual account: profit halved. New
Gazette: capital increase of 250k. New

News about who you follow, reason included.

Databakkes Pro · first month free

Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.

Management

Caroline Cassiman
CASSIFARMA

Behind CASSIFARMA is Caroline Cassiman. The shares are held by Caroline Cassiman. It owns 50% of Biloba Kessel-Lo and 50% of Biloba Heverlee itself.

See the full network in the app

Directors

According to the 2025 annual accounts

Caroline Cassiman

Director

Is a shareholder

Also active at: BILOBA HEVERLEE, BILOBA KESSEL-LO

Shareholders

Caroline Cassiman · director

Participations

Establishments

Establishment units

Physical locations of this company

Registered office

Familie de Bayostraat 55

3000 Leuven

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

Details

Company number
0727.381.719
VAT number
BE 0727.381.719
Registered office
Familie de Bayostraat 55, 3000 Leuven
Names & denominations
CASSIFARMA
Enterprise type
Rechtspersoon
Legal form
Private limited company
Legal situation
Normale toestand
Start date
22 May 2019
Peppol
Active · Active since 15 May 2025
Activities · NACE

Detailhandel in farmaceutische producten

Frequently asked questions

What is the enterprise number of CASSIFARMA?
The enterprise number of CASSIFARMA is BE0727381719.
What is the address of CASSIFARMA?
The registered office of CASSIFARMA is located at Familie de Bayostraat 55, 3000 Leuven.
When was CASSIFARMA founded?
CASSIFARMA was founded on 22 May 2019.
What is the main activity of CASSIFARMA?
The main activity of CASSIFARMA is "Detailhandel in farmaceutische producten" (NACE code 47730).
Does CASSIFARMA have a website?
No website is currently known for CASSIFARMA.
How much profit did CASSIFARMA make in 2025?
CASSIFARMA posted a profit after taxes of € 66,323 in financial year 2025.
What is the revenue of CASSIFARMA?
As a small company, CASSIFARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 114,699.
How many employees does CASSIFARMA have?
According to the 2025 annual accounts, CASSIFARMA has 0 full-time equivalents (FTE).
Where can I find the annual accounts of CASSIFARMA?
CASSIFARMA files its annual accounts with the Central Balance Sheet Office of the National Bank of Belgium. The key figures for recent financial years are available for free on this page.
Who are the directors of CASSIFARMA?
According to the 2025 annual accounts, the directors of CASSIFARMA are: Caroline Cassiman.
Who owns CASSIFARMA?
Behind CASSIFARMA is Caroline Cassiman. The shares are held by Caroline Cassiman. It owns 50% of Biloba Kessel-Lo and 50% of Biloba Heverlee itself.
Who are the shareholders of CASSIFARMA?
According to the 2025 annual accounts, the shareholders of CASSIFARMA are: Caroline Cassiman.